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Background: Seronegative rheumatoid arthritis (SRA) is a condition that is not well 
understood and difficult to confirm by a conventional diagnostic process. We aimed to 
quantify the potential cost-savings of an alternative diagnostic process (ADP) imaging- 
based, for patients with presumptive SRA from everyday clinical practice.
Methods: We performed a retrospective analysis for patients with presumptive SRA who 
tested negative for both rheumatoid factor and anti-cyclic citrullinated peptide antibodies, 
through an ADP imaging-based, that is a standard clinical practice in our center. After we 
confirmed the diagnosis of SRA or reclassified patients in terms of another proper diagnosis, 
we estimate direct costs in two scenarios: a conventional and ADP. We compared the cost of 
RA treatment during the first year against the cost of the most misdiagnosed treatment 
(osteoarthritis) found after applying the ADP to determine potential cost-savings.
Results: We included 440 patients with a presumptive diagnosis of SRA. According to the 
imaging-based ADP, SRA was confirmed in 106/440 (24.1%), unspecified RA in 9/440 
(2.0%), and osteoarthritis in 325/440 (73.9%) of those patients. Although the costs of 
conventional diagnosis per patient is lower than those of ADP ($59,20 USD vs $269,57 
USD), we found a potential drug cost-savings of $1,570,775.20 US Dollars after 1 year of 
correct treatment.
Conclusion: An alternative diagnosis process, including X-rays, US and MRI imaging, and 
clinical and blood-test assessment, not only increased diagnostic certainty in patients referred 
for evaluation of presumptive SRA but also suggested a potential cost-savings in pharma-
cological treatments avoided in misdiagnosed patients.
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Background
The 2010 Rheumatoid Arthritis (RA) classification criteria of the American College 
of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) 
are based on clinical (joint involvement and duration of symptoms), serologic, and 
acute-phase reactant domains, allowing the identification of patients at early disease 
stages who may benefit from the institution of early treatment.1
Because serological status is of paramount importance for the diagnosis, prog-
nosis, and treatment of RA,2 we classified it as seropositive (ICD-10 code M059) or 
seronegative (ICD-10 code M060) in terms of the seropositivity —or seronegative 
— of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies 
(ACPA).
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Seronegative RA (SRA) is a condition that is not well 
understood and difficult to confirm by a conventional diag-
nostic process, with high probabilities of its being con-
fused with other inflammatory arthropathies3,4 and 
requiring a consultation with an expert rheumatologist. 
Misdiagnosis of SRA could be more frequent in patients 
in whom presumptive SRA is seronegative for both RF 
and ACPA, but still be positive for clinical domains.
Although radiography (X-ray) is the gold standard for 
imaging in RA, this tool is insensitive for detecting bone 
erosions or inflammatory changes within the joint tissues 
during the earliest stages of the disease process.3,5
Several studies have shown that magnetic resonance 
imaging (MRI) is a sensitive and reproducible imaging 
tool for the diagnosis, follow-up, and assessment of both 
the inflammatory activity and the structural damage of the 
disease, and for the prognosis of patients with RA. This 
advanced imaging technology permits direct visualization 
of the anatomical structures that may be involved in the 
disease’s inflammatory process from its earliest stages.6
In the same way, ultrasound (US) allows an accurate 
evaluation of RA elementary lesions such as synovitis, 
tenosynovitis, and erosions, with direct visualization of 
early inflammatory and destructive joint changes.3,5,7 
Both imaging techniques (MRI and US) are efficient meth-
ods for the diagnosis, monitoring, and prognostication of 
early RA, avoiding the potential costs from unnecessary 
treatments deriving from misdiagnosis.8
For some time, in our center, we had observed that 
there is a high percentage of patients with osteoarthritis 
but with a diagnosis of seronegative RA; we believe that it 
is because the ACR/EULAR 2010 classification criteria 
commonly are used for guiding the diagnosis and the 
criteria have a weakness: you do not need RF or ACPA 
to make the diagnosis; using the clinical domain, a high 
ESR/CRP and the criterion of time, you can ¨make¨ the 
diagnosis; on the other hand, negative RF and ACPA do 
not give ¨points¨.
For this reason, in our center we have in last years, 
defended the position that even having a typical clinical 
picture of RA, if the patient´s RF and anti-CCP are nega-
tive, the diagnosis of seronegative RA should be con-
firmed by imaging, using the conventional X-rays, the 
magnetic resonance imaging (MRI) and the ultra-
sound (US).
An alternative diagnostic process (ADP) combining 
clinical criteria, laboratory tests of RF and ACPA, and 
imaging techniques as X-rays, MRI and US may be 
beneficial for improving the early detection and proper 
diagnosis of RA. According to these considerations, we 
aimed to evaluate the potential cost-savings related to the 
misdiagnosis and treatment of presumptive SRA by means 
of an ADP developed at a specialized in RA center 
(Center) from a healthcare perspective.
Methods
We developed a retrospective everyday clinical-practice data 
analysis from the clinical records of patients with a diagnosis 
of presumptive seronegative RA who were referred to 
a specialized Center for the provision of rheumatologic care.
This research did not involve the collection or use of 
individually identifiable health-related data. All clinical 
records were de-identified in order to preserve the patient’s 
privacy by assigning an identification number to each 
subject. Anonymous patient-data inputs were stored and 
analyzed in line with ethical compliance.
Inclusion and Exclusion Criteria
We analyzed electronic health records between July 2016 
and June 2017, for all patients referred to the Center by 
their insurance companies or payers with a presumptive 
diagnosis of seronegative RA. Patients were included if 
they tested negative for both RF and ACPA biomarkers, 
but fulfilled the classification criteria of RA according to 
ACR/EULAR 2010 classification criteria.1
We excluded patients without typical clinical symp-
toms of RA, with a sole serological (RF or ACPA) nega-
tive test, patients younger than 18 years of age, those with 
juvenile-onset idiopathic arthritis, patients with 
spondyloarthritis,9 those with other autoimmune disorders 
like systemic lupus erythematosus,10 Sjogren syndrome,11 
or those not fulfilling the clinical domains of ACR/ 
EULAR 2010 classification criteria.1
Ethics
According to Resolution 8430 of 1993 from the Ministry 
of Health of Colombia, this research presents no risks to 
patients; therefore, this study does not need approval from 
the ethics committee. The authors declare to adhere to the 
Declaration of Helsinki in all aspects of ethics. This study 
was approved by the Institutional Review Board of 
BIOMAB IPS, act number 007 of 27 July, 2017 (code 
GC.IN.01.FR.03). All patients had previously signed 
informed consent for data use; the database was anon-
ymized to protect the confidentiality and privacy of 
patients.
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Alternative Diagnostic Process
Figure 1 describes the ADP algorithm used for confirming 
diagnosis of seronegative RA. As mentioned a little above, 
the procedure called alternative diagnostic process (ADP) 
is a standard practice in our center for several years that 
has been applied in patients with a presumptive diagnosis 
of seronegative RA, and it was established to avoid ser-
onegative RA false positives diagnoses. Patients were 
assessed by at least one imaging technique (US, X-ray, 
or MRI) according to the specialized Center’s ADP 
process.
First, the patient with symptoms suggestive of RA and 
who already has a negative RF and ACPA depending on 
the time of evolution is subjected to imaging; if the disease 
has more than 2 years of evolution, X-rays of the hands 
and feet are performed; in case that erosions are observed, 
the diagnosis of seronegative RA is confirmed, but if there 
are no erosions or typical chronic changes of RA, the 
patient undergoes to an US of the hands and feet, which 
is considered positive for RA if are observed at least two 
zones of Power Doppler and/or synovitis greater than or 
equal to grade two; in case of disease evolution less than 2 
years, an US was performed  without previusly X-ray.
In those patients whose ultrasound is not conclusive, 
they undergo to MRI, where to confirm the diagnosis of 
seronegative RA, erosions and/or edema of the bone mar-
row without/with associated synovitis must be observed.
The Ultrasound (US) scanning protocol included the 
following bilateral anatomical areas: wrists, 1–5 metacar-
pophalangeal joints; 1–5 proximal interphalangeal joints, 
and 1–5 metatarsophalangeal joints, and the following 
tendons: 2–6 extensor wrist compartments; 2–5 digital 
flexor tendons of the hands, and posterior tibial tendons.
We employed an Esaote MyLab7TM (Genoa, Italy) 
ultrasound scanner equipped with a linear high-frequency 
(6–18 MHz) transducer. Gray-scale synovitis was defined 
according to OMERACT recommendations.12,13 For each 
synovial recess, B-mode synovitis and power Doppler 
were quantified utilizing a semi-quantitative scale accord-
ing to Szkudlarek et al.14
According to the specialized Center ADP algorithm, 
MRI was performed in patients whose US examination 
showed power Doppler grade 1 or gray-scale synovitis 
grade 1 in more than two joints, using a Multiva 1.5T 
Philips MRI system. OMERACT recommendations of 
basic MRI sequences and definitions in RA joint patholo-
gies were employed.6 We did not use gadolinium contrast 
enhancement. Magnetic resonance (MR) images were read 
by a Radiologist trained in RAMRIS-Scoring, who was 
blinded to clinical data. Images were evaluated for syno-
vitis, bone-marrow edema, and erosions, according to 
OMERACT 2016 RAMRIS.6
Clinical classification of patients as seronegative RA, 
osteoarthritis, or another proper diagnosis, was performed 
combining the clinical criteria with the results of the 
imaging studies, as depicted in Figure 1.
Cost-Analysis of Diagnosis and Treatment
In this study, we assumed that misdiagnosed patients with 
seronegative RA may experience a higher cost of medical 
care, generated through the implementation of comprehen-
sive medical care, including unnecessary laboratory tests, 
specialist’s follow-up visits, treatments, and their potential 
adverse effects. To compare the misdiagnosis and correct 
diagnosis of seronegative RA, we estimated direct medical 
costs for diagnosis and treatment according to the disease. 
We performed a cost-analysis in two scenarios:
1. Conventional RA diagnosis. This scenario reflects, 
as closely as possible, the current recommendations 
for the diagnosis and treatment of RA.1 Also, it 
describes the cost-of-illness for a patient with pre-
sumptive RA diagnosed through a consultation with 
a Rheumatologist and laboratory tests, including RF 
and ACPA acute-phase reactants (erythrocyte sedi-
mentation rate) and x-rays of hands and feet. We 
also included pharmacologic treatment (conven-
tional and biologic DMARD), glucocorticoids, 
NSAID, and analgesics. Here, we assumed that all 
patients were diagnosed and treated as having RA.
2. Alternative RA diagnosis process: In this scenario, 
patients with presumptive RA are screened through 
the specialized Center ADP algorithm depicted in 
Figure 1. We performed the diagnosis through con-
sultations with a Rheumatologist, laboratory test 
(RF, ACPA, and erythrocyte sedimentation rate) 
determinations, hands and feet x-rays, US, and 
MRI. This ADP algorithm may potentially increase 
diagnostic accuracy, thus minimizing false positives 
diagnosis of RA.
In this latter scenario, not all patients were diagnosed with 
seronegative RA: a proportion of the patients were diag-
nosed with OA or had an alternative diagnosis. To describe 
the potential cost-savings due to the implementation of the 
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Figure 1 Alternative Diagnosis process (ADP): Diagram describing the diagnosis and the number of patients according to the point-in-process classification.
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specialized Center ADP algorithm, direct medical costs 
based on consultations with Medical Specialists, pharma-
ceutical treatment, and laboratory and imaging tests during 
the first year of treatment were estimated based on ACR 
and EULAR recommendations for RA and OA.15–18
Direct medical costs were estimated using the recommen-
dations and guidelines from the Manual for the Preparation 
of Economic Evaluations in Health, published by the Institute 
of Technological Evaluation in Health (IETS),19 the official 
agency for health technology assessment in Colombia. We 
also followed Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS) statements for accurate 
reporting in the health economic evaluation.20
We estimated the costs of pharmacological treatments 
from tariffs reported from: a) Circulars of the National 
Commission of the prices of medicines and medical 
devices, which set maximal prices for some drugs in 
Colombia, and b) The Price Information System of 
Medicines (SISMED, the official source of the prices of 
drugs and sales-volume information.21
Because the unit value and market share of drugs for 
RA and OA were both known, we estimated a weighted 
mean cost, with its minimal and maximal costs. The costs 
of laboratory and imaging tests were processed from 
national prices, ie, Instituto de Seguros Sociales 2001 
plus 30%, as recommended by IETS.19
Statistical Analysis
A descriptive analysis of the characteristics of patients and 
classification of diagnosis was developed using STATA 
V13 software. In addition, data from medical costs were 
collected and analyzed in Microsoft Excel 365. To report 
results, mean, minimal and maximal (Min-Max) costs per 
patient were estimated. All costs were expressed in 2017 
prices and were converted into US dollars (USD), using 
the mean exchange rate from 01/01/2017 to 12/31/2017, 
where 1 USD = $2,951.30 Colombian pesos (COP).
Results
Patients’ Characteristics
A total of 440 patients with a mean age of 58 years 
(Standard deviation [SD] ± 12.3 years) were included in 
the analysis; of these, 356/440 (80.1%) were female. The 
proportion of patients with more than 2 years since the 
onset of a joint symptom was 368/440 (83.6%). According 
to the specialized Center’s ADP algorithm, we assessed 
369/440 (83.9%) patients by x-ray, 344/440 (78.1%) by 
US, and 58/440 (13.1%) by MRI.
Imaging Assessment
X-ray assessment showed that 12/369 (3.3%) patients had 
bone erosion consistent with a diagnosis of seronegative 
RA. Nineteen percent were positive for OA changes 
(asymmetric joint-space narrowing, osteophyte formation, 
subchondral sclerosis), while the remaining 273/369 
(62.3%) evidenced no joint abnormalities (normal 
x-rays). We assessed by US the following patients: 1) 
those with normal results by x-ray, and 2) those with 
fewer than 2 years of disease duration since the onset of 
symptoms.
As revealed in Figure 1, US assessment demonstrated 
that 74/344 (21.5%) patients had elementary inflammatory 
lesions (gray-scale synovitis and power Doppler signals) 
or structural changes (erosions), suggesting the presence of 
seronegative RA, while 1.7% exhibited normal US results 
and 210/344 (61%) displayed changes compatible with 
a diagnosis of OA.
We classified the US findings as inconclusive in 58/344 
(16.8%) patients (power Doppler = 1 or grey-scale syno-
vitis = 1, according to Figure 1). MRI evaluation permitted 
us to reclassify 20/58 patients (34.4%) with erosions or 
subchondral bone-marrow edema as seronegative RA, 
whereas 31/58 (53.4%) were positive for OA changes. 
The remaining 7/58 (12%) patients showed no MRI 
abnormalities.
Final Diagnosis
According to the International Classification of Diseases 
10th Revision (ICD-10 classification), at the end of the 
ADP algorithm, we diagnosed 106/440 (24.1%) patients as 
having seronegative RA. We classified the remaining 9/ 
440 patients (2.0%) as having unspecified arthritis and 
325/440 (73.9%) as having OA.
We identified the patients classified as seronegative RA 
as follows: 13/106 (12.3%) patients by x-ray; 72/106 
(67.9%) patients by US, and the remaining 21/106 
(19.8%) patients by MRI. After applying the ADP, OA 
was the most frequent misdiagnosis with 206/325 (63.4%) 
of these cases identified by US.
Cost of Diagnosis and Treatment
Table 1 presents the direct medical cost related to the 
diagnosis of RA. The conventional total diagnostic cost 
was estimated at $59.20 USD (of which 27% was due to 
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consultations with the Rheumatologist). The cost of the 
alternative diagnosis process was $269.57 USD. The 
largest share of this cost was related to the use of 
imaging techniques, including x-rays, US, and 
MRI (65.2%).
Table 2 shows that the estimated mean cost 
per seronegative RA patient for 1 year of follow-up was 
$5,419.3 USD (range, $5,125.8 USD-$5,787.7 USD), 
while Table 3 presents the mean cost for OA as $526.3 
USD (range, $394.5 USD-$867.5 USD). The highest cost 
in seronegative RA was related to the pharmacological 
treatment, accounting for $5,332.6 USD (98.4% of the 
total cost; see Table 2). For OA, the proportion of phar-
macological treatment in the total cost of the treatment 
per year was 92.2%.
We calculated the cost of biologic therapy ($4,211.0 
USD per year; see Table 2) assuming that these biodrugs 
were included in month 6 of treatment -after conventional 
DMARD therapy failure- representing the highest cost of 
pharmaceutical therapy.
Assuming patients with seronegative RA without bio-
logic therapy, the cost of treatment continued to be higher 
than that of OA. According to Table 2, we estimated the 
cost per year with DMARD therapy as $1,123.6 USD 
(sum of monotherapy, combined therapy, glucocorticoids, 
and analgesics) compared with that of OA, with a cost of 
$526.3 USD
Potential Cost-Savings
Table 4 depicts the comparison of the two cost scenarios. 
The cost per patient in the conventional scenario (which 
includes $59.20 USD for common diagnosis and 
$5,419.13 USD for RA treatment per year) was 
$5,478.33 USD. In this manner, treating 440 patients 
with presumptive seronegative RA would represent an 
economic burden of $2,384,474.2 USD for the third 
payer. The alternative diagnostic-process scenario esti-
mated an ADP of $269.6 USD plus $5,419.3 USD of 
a cost per patient for RA treatment, totaling $5,715.9 
USD for seronegative RA and $296.6 USD plus $526.3 
USD (for a total of $822.9 USD) for OA, respectively.
In this scenario, we confirmed 106 patients with ser-
onegative RA and 325 patients with OA. The total eco-
nomic burden per year, assuming the treatment in the 
431 patients in this scenario, was $839,748.5 USD. In 
this manner, we found a potential cost-savings by using 
the ADP algorithm of $1,570,775.2 USD per year 
(Table 4).
Discussion
This study showed how an ADP algorithm that combines 
imaging and laboratory tests, along with clinical criteria, 
could introduce potential savings in the costs of medical 
care from the perspective of the third payer.
Some studies suggest that the two serotypes of RA - 
seronegative and seropositive- may reflect different entities. 
Despite their clinical overlap, they differ in terms of genetic 
basis, immunopathology, differential diagnosis, treatment, 
and even patient outcome; therefore, proper differentiation 
from the early disease stages is of utmost importance.1,3
Our results, based on everyday clinical-practice evi-
dence from a single Center, also demonstrated how the 
use of imaging techniques improves the accuracy of the 
diagnosis of double-seronegative RA and identifies other 
sources of joint damage that indicate alternative differen-
tial diagnoses. Thus, an alternative imaging-based diag-
nostic process could assist in the evaluation of the 
Rheumatologist in cases where RA serologic biomarkers 
are negative despite the presence of clinical criteria, 
enabling the diagnosis of seronegative RA, or suggesting 
an alternative diagnosis, such as OA.
Evaluating the costs of diagnostic interventions and 
medical treatments is important, but is often a difficult 
task. Cost estimates related to medical care must include 
not only the costs of diagnostic tests (laboratory and 
Table 1 Direct Costs Related to Diagnosis of Presumptive 
Seronegative RA












2 $ 16.11 3 $ 24.05
Rheumatoid factor test 1 $ 14.58 1 $ 14.58
ACPA test 1 $ 13.71 1 $ 13.71
Sedimentation rate 1 $ 0.65 1 $ 0.65
Foot X-Ray 1 $ 7.07 1 $ 7.07
Hand X-Ray 1 $ 7.07 1 $ 7.07
Ultrasound ** 1 $ 26.99
MRI* ** 1 $ 175.43
Total $ 59.20 $ 269.57
Notes: **Cost not applied; *MRI was required in 13% of patients; This table 
describes the cost by the conventional diagnosis and the cost using the ADP. 
Abbreviations: ACPA, Anti-cyclic citrullinated peptide antibodies; MRI, Magnetic 
resonance imaging.
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imaging), but also the costs of the clinical follow-up and 
pharmacological management resulting from the diagnosis 
based on the test results.22 These subsequent costs are 
often considerably higher than the initial diagnostic costs 
of a comprehensive evaluation, especially if they include 
biological therapy or high-cost drugs.
The effective use of diagnostic imaging technologies in 
guidelines and recommendations often confers no or solely 
low-level evidence for their cost-effectiveness. Our find-
ings are consistent with previous studies demonstrating 
that the use of US in the diagnosis process increases 
diagnostic certainty for inflammatory arthritis and 
RA.23,24 Furthermore, EULAR recommendations for the 
use of imaging in RA also suggest the use of MRI or US in 
cases of diagnostic doubt, instead of that of clinical criteria 
alone (recommendation 1).25 Another study evidenced 
how the use of US could be useful to detect bone erosion 
suggestive of RA and to detect differences with other joint 
pathologies resulting in bone erosions,26 thus facilitating 
differential diagnosis.
According to these results, even when the majority 
of the patients included had undergone more than 2 
years of disease duration from the beginning of bone 
erosions; only 12% of patients had seronegative RA. 
On the other hand, a study on radiographic damage 
analyzing 250 patients with seronegative RA and 
Table 2 Estimation of Direct Cost of RA Treatment* in the First Year After Diagnosis per Patient
Activity MDA-HDA**
Cost (USD)
3 Months 3–6 Months 6–9 Months 9–12 Months Total per Year
Mean (Min–Max) Mean (Min–Max) Mean (Min–Max) Mean (Min–Max) Mean (Min–Max)
Pharmacological treatment
Monotherapy
MTX $464.8 (464.6–473.9) $464.8 (464.6–473.9)
Combined therapy
MTX $464.8 (464.6–473.9) $464.8 (464.6–473.9)
SSZ $12.5 (10.6–17.2) $12.5 (10.6–17.2)









Prednisone $2.7 (2.6–4.4) $2.7 (2.6–4.4) $5.4 (5.3–8.8)
Folic Acid $0.6 (0.6–1.2) $0.6 (0.6–1.2) $0.6 (0.6–1.2) $0.6 (0.6–1.2) $2.6 (2.2–4.9)
Analgesics
Acetaminophen $15.1 (9.2–33.5) $15.1 (9.2–33.5) $15.1 (9.2–33.5) $15.1 (9.2–33.5) $60.4 (36.9–133.9)
Laboratory
Complete blood count $4.9 (4.9–4.9) $4.9 (4.9–4.9) $4.9 (4.9–4.9) $4.9 (4.9–4.9) $19.7 (19.7–19.7)
Transaminases $6.2 (6.2–6.2) $6.2 (6.2–6.2) $6.2 (6.2–6.2) $6.2 (6.2–6.2) $24.7 (24.7–24.7)
Creatinine $1.5 (1.5–1.5) $1.5 (1.5–1.5) $1.5 (1.5–1.5) $1.5 (1.5–1.5) $5.9 (5.9–5.9)
TB $2.2 (2.2–2.2) $2.2 (2.2–2.2)
Consultation











Notes: *Standard treatment based on treat to target strategy; **MDA-HAD, Moderate and High Disease Activity; This table shows the cost related to the drug treatment of 
a patient with RA, according to the scheme proposed by the ACR guideline for the treatment of patients living with RA.
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definite RA demonstrated evidence of major damage 
in patients with a lengthy disease evolution, with no 
statistical differences for negative or positive blood 
biomarkers.27
Our study could not confirm the notion that radiogra-
phy detects a higher proportion of bone erosions in 
patients with a longer disease duration. An alternative 
interpretation is that it is difficult to remember precisely 
the onset of the disease when the latter entertains an 
insidious type of onset as opposed to the acute onset of 
symptoms that are more easily recognized by patients. The 
lag in the detection of RA could also be reduced by 
training in the wide range of the early symptoms of RA 
in primary-care medical providers.28
Evidence has demonstrated the effectiveness and efficiency 
of implementing new diagnostic strategies for RA.6,29–35 The 
potential cost-analysis that we performed revealed that apply-
ing an ADP algorithm increased the precision of the diagnosis 
and could represent potential savings of up to $1.44 million 
USD per year to the Colombian health system.
Table 3 Estimation of Direct Cost of OA Treatment in the First Year After Diagnosis per Patient*
Activity Dosage Cost (USD)
Moderate Pain Severe Pain Mean Cost per Year (USD)
Mean (Min–Max) Mean (Min–Max) Mean (Min–Max)
Pharmacological treatment
Glucosamine/chondroitin sulfate 1500mg/1200mg/day $80.5 (69.5–116.6) $80.5 (69.5–116.6) $80.5 (69.5–116.6)
Acetaminophen 3000mg/day $60.4 (36.9–133.9) $60.4 (36.9–133.9) $60.4 (36.9–133.9)
Tramadol 10/100 mg/day $5.4 (3.4–9.8) $5.4 (3.4–9.8)
Etoricoxib 90 mg/day $338.8 (243.6–566.1) $338.8 (243.6–566.1)
Laboratory
Complete blood count 2 per year $9.8 (9.8–9.8) $9.8 (9.8–9.8) $9.8 (9.8–9.8)
Transaminases 2 per year $12.3 (12.3–12.3) $12.3 (12.3–12.3) $12.3 (12.3–12.3)
Creatinine 2 per year $3.0 (3.0–3.0) $3.0 (3.0–3.0) $3.0 (3.0–3.0)
Consultation
Rheumatologist 2 per year $16.0 (16.0–16.0) $16.0 (16.0–16.0) $16.0 (16.0–16.0)
Total cost per year $526.3 (394.5–867.5)
Notes: *Standard treatment based on consensus PANLAR for the treatment of OA. 2016; This table shows the cost associated with the drug treatment of patients with 
OA.
Table 4 Potential Cost-Savings Due to the Application of an Alternative Diagnosis Process
Cost per Patient (USD) Cost per Group of Patients (USD)
Mean (Min–Max) Freq. Mean (Min–Max)
Conventional RA 
diagnosis scenario
Conventional diagnosis $59.2 (59.2–59.2) 440 $26,049.5 (26,049.5–26,049.5)
RA treatment per year $5,419.3 (5,125.8–5,787.7) 440 $2,384,474.2 (2,255,352.3–2,546,566.4)
Total cost per year $2.410.523,8 (2.281.401,9–2.572.615,9)
Alternative RA diagnosis 
process scenario
ADP* $269.6 (269.6–269.6) 440 $45,492.2 (45,492.2–45,492.2)
RA treatment per year $5,419.3 (5,125.8–5,787.7) 106 $623,214.9 (589,467.1–665,579.8)
OA treatment per year $526.3 (394.5–867.5) 325 $171,041.5 (128,198.7–281,942.5)
Total cost per year $839,748.5 (763,158.0–993,014.5)
Cost saving per year $1,570,775.2 
(1,518,243.9–1,579,601.4)
Notes: *440 patients diagnosed with ADP: labs and imaging tests reported at figure 3 (73% of patients were diagnosed with Ultrasound and 13% with MRI); This table 
presents the cost-saving estimation per patient and the group of patients analyzed in the period when the ADP was applied.
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Adding US and MRI to the diagnosis process represented 
a cost of $202.42 USD per patient ($89,064.8 USD for the 440 
analyzed patients). At first glance, our results imply that diag-
nostic costs would increase considerably, but this result could 
be counteracted by the avoided cost resulting from the correct 
diagnosis and treatment of seronegative RA and OA.
Our study has limitations that must be considered when 
generalizing its results. The main limitation was related to 
patients classified as having OA. These patients were not 
followed up by US to check their disease evolution. 
However, the majority of these patients continue to be 
treated at the specialized Center; their follow-up status 
will be included in a subsequent analysis to verify their 
outcomes. Another limitation is that we presented only 
a single-Center experience; therefore, the study lacks con-
trol/contrasting data from different centers devoted to the 
attention of rheumatic diseases. The retrospective design of 
the study represents an additional limitation. Finally, 
researchers cannot control exposure or outcome assessment, 
and instead rely on others for accurate record keeping.
Since our cost comparison comprises an approach of the 
current RA diagnostic process in Colombia vs one specia-
lized-Center ADP algorithm, the potential cost-savings due 
to the implementation of this ADP algorithm could not be 
extrapolated to the entire Colombian health system. It 
would be interesting to conduct a cost-effectiveness analy-
sis of this strategy to follow a cohort of patients during their 
lifespan and estimate its potential cost-savings.
The strength of this research lies in that it is based on the 
everyday clinical practice of a disease management model of 
care that could improve the diagnostic certainty of seronegative 
RA, in which US could exert an influence on Rheumatologists 
in their decisions on making a diagnosis or on re-referring the 
patient, as shown by Rezaei et al.23
Conclusions
A well-defined process of diagnosis, including imaging, clin-
ical, and blood-test domains significantly increased diagnostic 
certainty in patients referred for the evaluation of presumptive 
seronegative RA. Moreover, the use of US and MRI is useful 
for identifying early damage and synovitis in the diagnosis of 
seronegative RA and for identifying another proper diagnosis.
This entire process also demonstrates potential pharmaco-
logical cost-savings due to the improving certainty in the 
diagnostic approach, avoiding unnecessary treatments of mis-
diagnosed patients. Even when the process of diagnosis 
implies an incremental cost by using imaging, the potential 
cost-savings in RA pharmacological treatments for patients 
with another misdiagnosis per year is well above that of the 
incremental cost of diagnosis; thus, it must be taken into 
consideration.
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